Targeted delivery of Lu-177 to tumor vasculature

将 Lu-177 靶向递送至肿瘤脉管系统

基本信息

  • 批准号:
    8332296
  • 负责人:
  • 金额:
    $ 98.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-13 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Currently available anti-angiogenic drugs inhibit VEGF/VEGFR signaling, which leads to transient vascular regression followed by rebound of drug-resistant vasculature, which significantly decrease the therapeutic efficacy of very expensive anti-angiogenic treatment. To overcome this problem, we are developing a cytotoxic 177Lu radiopharmaceutical, scVEGF/Lu. This radiopharmaceutical is based on engineered single-chain VEGF (scVEGF) and it accumulates in tumor endothelial cells via endocytosis mediated by overexpressed VEGFR-2. In Phase I we optimized the composition of scVEGF/Lu, assessed its radiotoxicity and dosimetry and performed initial therapeutic efficacy and mechanistic studies in orthotopic breast tumor models. Our results demonstrate that a single injection of a safe dose of scVEGF/Lu induces destruction of tumor vasculature sustainable for at least 30-35 days and a widespread apoptosis in tumor without significant overall radiotoxicity. In contrast, FDA-approved sunitinib and bevacizumab failed to induce sustainable destruction of tumor vasculature, suggesting potential advantages of scVEGF/Lu. In Phase II we will focus on late pre-clinical development of scVEGF/Lu as a novel component of anti- angiogenic therapy, using orthotopic mouse models of recurrent breast cancer, including a model of human triple negative breast cancer. First, we will establish the dose- and time-dependences for scVEGF/Lu-induced destruction of tumor vasculature and potential roles of overexpressed endogenous VEGF and immunocompetent environment in therapeutic efficacy of scVEGF/Lu. Next, we will establish optimal sequence for scVEGF/Lu-doxorubicin combination as adjuvant therapy for recurrent breast cancer. Considering that scVEGF is a physiologically active protein, we will also establish the safety profile for scVEGF-PEG-DOTA conjugate. We expect that by the end of Phase II of the project we will have evidence-based indications for safe use of scVEGF/Lu in adjuvant anti-angiogenic therapy for breast cancer. We will also have a GLP-grade for dosimetry studies. This data will be used for filing IND or eIND with FDA for Phase I clinical trials with scVEGF/Lu in breast cancer. We believe that this novel targeted radiopharmaceutical may provide a new line of attack on breast cancer, and eventually will be explored for treatment of other cancers.
描述(由申请人提供):目前可用的抗血管生成药物抑制VEGF/VEGFR信号,导致短暂性血管消退,随后耐药血管反弹,这显著降低了非常昂贵的抗血管生成治疗的疗效。为了克服这个问题,我们正在开发一种具有细胞毒性的放射性药物,scVEGF/Lu。这种放射性药物基于工程单链VEGF (scVEGF),它通过过表达的VEGFR-2介导的内吞作用在肿瘤内皮细胞中积累。在I期研究中,我们优化了scVEGF/Lu的组成,评估了其放射毒性和剂量学,并在原位乳腺肿瘤模型中进行了初步的治疗效果和机制研究。我们的研究结果表明,单次注射安全剂量的scVEGF/Lu诱导肿瘤血管破坏持续至少30-35天,肿瘤细胞广泛凋亡,无明显的总体放射毒性。相比之下,fda批准的舒尼替尼和贝伐单抗未能诱导肿瘤血管的持续破坏,提示scVEGF/Lu的潜在优势。在II期,我们将专注于scVEGF/Lu作为抗血管生成治疗的新成分的后期临床前开发,使用复发性乳腺癌的原位小鼠模型,包括人类三阴性乳腺癌模型。首先,我们将建立scVEGF/Lu诱导的肿瘤血管破坏的剂量和时间依赖性,以及过表达的内源性VEGF和免疫活性环境在scVEGF/Lu治疗效果中的潜在作用。接下来,我们将建立scVEGF/ lu -阿霉素联合辅助治疗复发性乳腺癌的最佳序列。考虑到scVEGF是一种具有生理活性的蛋白,我们还将建立scVEGF- peg - dota偶联物的安全性。我们预计,在项目II期结束时,我们将获得基于证据的适应症,证明scVEGF/Lu在乳腺癌辅助抗血管生成治疗中的安全使用。我们也将有glp等级用于剂量学研究。该数据将用于向FDA提交scVEGF/Lu在乳腺癌中的I期临床试验的IND或eIND。我们相信,这种新型靶向放射性药物可能为乳腺癌提供一条新的治疗途径,并最终将探索用于治疗其他癌症。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph M Backer其他文献

Joseph M Backer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph M Backer', 18)}}的其他基金

Clinical development of 18F PET tracer for imaging VEGF receptors
用于 VEGF 受体成像的 18F PET 示踪剂的临床开发
  • 批准号:
    8648418
  • 财政年份:
    2014
  • 资助金额:
    $ 98.56万
  • 项目类别:
Clinical development of 18F PET tracer for imaging VEGF receptors
用于 VEGF 受体成像的 18F PET 示踪剂的临床开发
  • 批准号:
    9017150
  • 财政年份:
    2014
  • 资助金额:
    $ 98.56万
  • 项目类别:
Targeted photoacoustic imaging of VEGF receptors in angiogenic vasculature
血管生成血管系统中 VEGF 受体的靶向光声成像
  • 批准号:
    8126616
  • 财政年份:
    2011
  • 资助金额:
    $ 98.56万
  • 项目类别:
Targeted delivery of Lu-177 to tumor vasculature
将 Lu-177 靶向递送至肿瘤脉管系统
  • 批准号:
    8204231
  • 财政年份:
    2011
  • 资助金额:
    $ 98.56万
  • 项目类别:
Targeted delivery of Lu-177 to tumor vasculature
将 Lu-177 靶向递送至肿瘤脉管系统
  • 批准号:
    7745604
  • 财政年份:
    2009
  • 资助金额:
    $ 98.56万
  • 项目类别:
Targeting anti-apoptotic drugs to failing cardiomyocytes
将抗凋亡药物靶向衰竭的心肌细胞
  • 批准号:
    7271618
  • 财政年份:
    2007
  • 资助金额:
    $ 98.56万
  • 项目类别:
VEGF-driven PET imaging of tumor angiogenesis
VEGF 驱动的肿瘤血管生成 PET 成像
  • 批准号:
    7327851
  • 财政年份:
    2007
  • 资助金额:
    $ 98.56万
  • 项目类别:
Molecular Targeted Imaging in Colon Cancer
结肠癌的分子靶向成像
  • 批准号:
    7405731
  • 财政年份:
    2007
  • 资助金额:
    $ 98.56万
  • 项目类别:
VEGF-based Targeted Imaging of Tumor Vasculature
基于 VEGF 的肿瘤脉管系统靶向成像
  • 批准号:
    7271615
  • 财政年份:
    2005
  • 资助金额:
    $ 98.56万
  • 项目类别:
VEGF-based targeted imaging of tumor vasculature
基于 VEGF 的肿瘤脉管系统靶向成像
  • 批准号:
    6882122
  • 财政年份:
    2005
  • 资助金额:
    $ 98.56万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 98.56万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 98.56万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 98.56万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 98.56万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 98.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 98.56万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 98.56万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 98.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 98.56万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 98.56万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了